McGuire Investment Group LLC Acquires Shares of 23,500 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

McGuire Investment Group LLC acquired a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, HoldingsChannel reports. The fund acquired 23,500 shares of the company’s stock, valued at approximately $159,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in RXRX. ARK Investment Management LLC lifted its holdings in Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after purchasing an additional 4,626,268 shares in the last quarter. State Street Corp lifted its holdings in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $8,250,000. Perceptive Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $5,769,000. Finally, Geode Capital Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Down 2.7 %

Shares of RXRX stock opened at $7.33 on Friday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $6.90 and its two-hundred day moving average is $6.95. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the prior year, the business earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several research reports. KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.75.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the sale, the director now directly owns 7,066,113 shares in the company, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,894 shares of company stock worth $279,279 over the last three months. Insiders own 15.75% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.